Extra precision docking studies of novel luteolin analogues for the inhibition of Tankyrase II

A theoretical-based approach toward novel cancer target

Aravinda Pai, Richard Lobo, Sanchari Basu-Mallik, B. S. Jayashree

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Introduction: Luteolin, a natural flavonoid is known to possess variety of pharmacological activity, particularly growth inhibition. Reports are available to substantiate the interaction of luteolin with tankyrase II, one of the key enzymes responsible for sustenance of telomeres and involved in promoting cellular function. Objective:In our study, we have identified synthetic analogues of luteolin from a chemical compound database (E molecule). After suitable modifications of these analogues, we have screened them for their binding affinity for the active site of tankyrase II (PDB ID: 4HKN). Methods: 15 analogues were subjected to the molecular docking process, which was executed using Glide™ module in Maestro Molecular Modeling platform (version 10.5) from Schrodinger, LLC, using both the standard precision (SP) as well as extra precision (XP) mode. Further, we also attempted to assess the ADME toxicity profiles of the compounds using QikProp application from Schrodinger, LLC. Result: In the present study, we have successfully identified 3 analogues (flav 10, flav 11, flav 12) which exhibited comparable dock scores (-10.02 -10.438 and -10.083 kcal/mol respectively) when compared to the standard luteolin (-11.472). Further, these 3 analogues also demonstrated favourable pharmacokinetic profiles as compared to luteolin. Conclusion: Therefore, the present study will provide insight for further structural modifications and aid in generating a suitable scaffold for enhanced binding affinity to tankyrase II. Future perspectives reside in attempting their synthesis, in vitro and in vivo evaluation to develop a novel anticancer agent.

Original languageEnglish
Pages (from-to)138-143
Number of pages6
JournalThai Journal of Pharmaceutical Sciences
Volume41
Issue number4
Publication statusPublished - 01-01-2017

Fingerprint

Tankyrases
Luteolin
Neoplasms
Chemical Databases
Telomere
Flavonoids
Antineoplastic Agents
Catalytic Domain
Pharmacokinetics
Pharmacology
Enzymes
Growth

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science

Cite this

@article{6c274eea96c94ae8b6030c37da66b55b,
title = "Extra precision docking studies of novel luteolin analogues for the inhibition of Tankyrase II: A theoretical-based approach toward novel cancer target",
abstract = "Introduction: Luteolin, a natural flavonoid is known to possess variety of pharmacological activity, particularly growth inhibition. Reports are available to substantiate the interaction of luteolin with tankyrase II, one of the key enzymes responsible for sustenance of telomeres and involved in promoting cellular function. Objective:In our study, we have identified synthetic analogues of luteolin from a chemical compound database (E molecule). After suitable modifications of these analogues, we have screened them for their binding affinity for the active site of tankyrase II (PDB ID: 4HKN). Methods: 15 analogues were subjected to the molecular docking process, which was executed using Glide™ module in Maestro Molecular Modeling platform (version 10.5) from Schrodinger, LLC, using both the standard precision (SP) as well as extra precision (XP) mode. Further, we also attempted to assess the ADME toxicity profiles of the compounds using QikProp application from Schrodinger, LLC. Result: In the present study, we have successfully identified 3 analogues (flav 10, flav 11, flav 12) which exhibited comparable dock scores (-10.02 -10.438 and -10.083 kcal/mol respectively) when compared to the standard luteolin (-11.472). Further, these 3 analogues also demonstrated favourable pharmacokinetic profiles as compared to luteolin. Conclusion: Therefore, the present study will provide insight for further structural modifications and aid in generating a suitable scaffold for enhanced binding affinity to tankyrase II. Future perspectives reside in attempting their synthesis, in vitro and in vivo evaluation to develop a novel anticancer agent.",
author = "Aravinda Pai and Richard Lobo and Sanchari Basu-Mallik and Jayashree, {B. S.}",
year = "2017",
month = "1",
day = "1",
language = "English",
volume = "41",
pages = "138--143",
journal = "Thai Journal of Pharmaceutical Sciences",
issn = "0125-4685",
publisher = "Thai Journal of Pharmaceutical Sciences",
number = "4",

}

TY - JOUR

T1 - Extra precision docking studies of novel luteolin analogues for the inhibition of Tankyrase II

T2 - A theoretical-based approach toward novel cancer target

AU - Pai, Aravinda

AU - Lobo, Richard

AU - Basu-Mallik, Sanchari

AU - Jayashree, B. S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Introduction: Luteolin, a natural flavonoid is known to possess variety of pharmacological activity, particularly growth inhibition. Reports are available to substantiate the interaction of luteolin with tankyrase II, one of the key enzymes responsible for sustenance of telomeres and involved in promoting cellular function. Objective:In our study, we have identified synthetic analogues of luteolin from a chemical compound database (E molecule). After suitable modifications of these analogues, we have screened them for their binding affinity for the active site of tankyrase II (PDB ID: 4HKN). Methods: 15 analogues were subjected to the molecular docking process, which was executed using Glide™ module in Maestro Molecular Modeling platform (version 10.5) from Schrodinger, LLC, using both the standard precision (SP) as well as extra precision (XP) mode. Further, we also attempted to assess the ADME toxicity profiles of the compounds using QikProp application from Schrodinger, LLC. Result: In the present study, we have successfully identified 3 analogues (flav 10, flav 11, flav 12) which exhibited comparable dock scores (-10.02 -10.438 and -10.083 kcal/mol respectively) when compared to the standard luteolin (-11.472). Further, these 3 analogues also demonstrated favourable pharmacokinetic profiles as compared to luteolin. Conclusion: Therefore, the present study will provide insight for further structural modifications and aid in generating a suitable scaffold for enhanced binding affinity to tankyrase II. Future perspectives reside in attempting their synthesis, in vitro and in vivo evaluation to develop a novel anticancer agent.

AB - Introduction: Luteolin, a natural flavonoid is known to possess variety of pharmacological activity, particularly growth inhibition. Reports are available to substantiate the interaction of luteolin with tankyrase II, one of the key enzymes responsible for sustenance of telomeres and involved in promoting cellular function. Objective:In our study, we have identified synthetic analogues of luteolin from a chemical compound database (E molecule). After suitable modifications of these analogues, we have screened them for their binding affinity for the active site of tankyrase II (PDB ID: 4HKN). Methods: 15 analogues were subjected to the molecular docking process, which was executed using Glide™ module in Maestro Molecular Modeling platform (version 10.5) from Schrodinger, LLC, using both the standard precision (SP) as well as extra precision (XP) mode. Further, we also attempted to assess the ADME toxicity profiles of the compounds using QikProp application from Schrodinger, LLC. Result: In the present study, we have successfully identified 3 analogues (flav 10, flav 11, flav 12) which exhibited comparable dock scores (-10.02 -10.438 and -10.083 kcal/mol respectively) when compared to the standard luteolin (-11.472). Further, these 3 analogues also demonstrated favourable pharmacokinetic profiles as compared to luteolin. Conclusion: Therefore, the present study will provide insight for further structural modifications and aid in generating a suitable scaffold for enhanced binding affinity to tankyrase II. Future perspectives reside in attempting their synthesis, in vitro and in vivo evaluation to develop a novel anticancer agent.

UR - http://www.scopus.com/inward/record.url?scp=85043335377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043335377&partnerID=8YFLogxK

M3 - Article

VL - 41

SP - 138

EP - 143

JO - Thai Journal of Pharmaceutical Sciences

JF - Thai Journal of Pharmaceutical Sciences

SN - 0125-4685

IS - 4

ER -